Hall R E, Clements J A, Birrell S N, Tilley W D
Flinders Cancer Centre, Flinders University of South Australia, Flinders Medical Centre, Bedford Park, Australia.
Br J Cancer. 1998 Aug;78(3):360-5. doi: 10.1038/bjc.1998.499.
Androgens regulate breast cancer cell proliferation via androgen receptor (AR)-mediated mechanisms. To investigate further the androgen-responsiveness of human breast tumours, we examined the immunohistochemical expression of the AR and two androgen-regulated proteins, prostate-specific antigen (PSA) and gross cystic disease fluid protein-15 (GCDFP-15), in 72 primary breast tumours. AR immunoreactivity was present in the nuclei of breast tumour cells and was correlated with oestrogen receptor (ER; P < 0.05) and progesterone receptor (PR; P < 0.01) status. PSA and GCDFP-15 immunoreactivity was present in the cytoplasm of tumour cells but not the adjacent stromal cells. AR-positive cells were present in 85% (61/72) of breast tumours, and 98% (43/44) of PSA-positive and 92% (44/48) of GCDFP-15-positive tumours were also positive for AR. Positive immunoreactivity for both PSA and GCDFP-15 in breast tumours was highly dependent on AR status (odds ratios of 24.0 and 4.5 respectively), but unrelated to age, ER and PR status and axillary lymph node involvement. PSA immunoreactivity was more frequently observed in moderate and well-differentiated tumours and was significantly (P < 0.001) associated with GCDFP-15 immunoreactivity. In conclusion, PSA and GCDFP-15 immunoreactivity was dependent on the presence of AR, but not ER or PR in primary breast tumours.
雄激素通过雄激素受体(AR)介导的机制调节乳腺癌细胞的增殖。为了进一步研究人类乳腺肿瘤对雄激素的反应性,我们检测了72例原发性乳腺肿瘤中AR以及两种雄激素调节蛋白——前列腺特异性抗原(PSA)和乳腺囊肿病液蛋白-15(GCDFP-15)的免疫组化表达。AR免疫反应性存在于乳腺肿瘤细胞的细胞核中,并且与雌激素受体(ER;P<0.05)和孕激素受体(PR;P<0.01)状态相关。PSA和GCDFP-15免疫反应性存在于肿瘤细胞的细胞质中,但不存在于相邻的基质细胞中。85%(61/72)的乳腺肿瘤中存在AR阳性细胞,并且98%(43/44)的PSA阳性肿瘤和92%(44/48)的GCDFP-15阳性肿瘤也为AR阳性。乳腺肿瘤中PSA和GCDFP-15的阳性免疫反应性高度依赖于AR状态(优势比分别为24.0和4.5),但与年龄、ER和PR状态以及腋窝淋巴结受累无关。PSA免疫反应性在中度和高分化肿瘤中更常见,并且与GCDFP-15免疫反应性显著相关(P<0.001)。总之,在原发性乳腺肿瘤中,PSA和GCDFP-15免疫反应性依赖于AR的存在,但不依赖于ER或PR。